Shire : Elections for the interim dividend

Elections for the interim dividend in respect of the six months to December 31,
2016

February 24, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the 'Company')
announced on February 16, 2017, an interim dividend of 25.70 US cents per
Ordinary Share payable on April 25, 2017, to shareholders on the register
of members at the close of business on March 10, 2017.

Holders of Ordinary Shares are notified that, in order to receive UK sourced
dividends via the Company's Income Access Share arrangements ('IAS
Arrangements'), they need to have submitted a valid IAS Arrangements election
form to the Company's Registrar, Equiniti, by no later than 5pm (GMT) on March
24, 2017.

Holders of Ordinary Shares are advised that:

  * any previous elections made using versions of the IAS Arrangements election
    form in use prior to February 16, 2016, and any elections deemed to have
    been made prior to April 28, 2016, are no longer valid; and

  * if they do not elect, or have not elected using the newly formatted IAS
    Arrangements election forms published on or after February 16, 2016, to
    receive UK sourced dividends via the Company's IAS Arrangements, their
    dividends will be Irish sourced and therefore incur Irish dividend
    withholding tax, subject to applicable exemptions.

    Internet links to the newly formatted IAS Arrangements election forms can
    be found at: http://investors.shire.com/shareholder-information/
    shareholder-forms.aspx

    For further information concerning the IAS Arrangements, please contact
    Equiniti (+44 (0) 121 415 7593). If you are in any doubt as to what action
    to take, please consult your tax advisor immediately.

    Oliver Strawbridge

    Senior Assistant Company Secretary

For further information please contact:

Investor Relations

Ian Karp                        ikarp@shire.com            +1 781 482 9018

Robert Coates                   rcoates@shire.com          +44 1256 894874

Media

Lisa Adler                      lisa.adler@shire.com       +1 617 588 8607

Debbi Ford                      debbi.ford@shire.com       +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people
with rare diseases. We strive to develop best-in-class products, many of which
are available in more than 100 countries, across core therapeutic areas
including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage
Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary
Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.

www.shire.com